| Previous Close | 0.7450 |
| Open | 0.7233 |
| Bid | 0.7001 x 3000 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.7022 - 0.7700 |
| 52 Week Range | 0.6500 - 2.7500 |
| Volume | 6,523 |
| Avg. Volume | 72,964 |
| Market Cap | 6.714M |
| Beta (3Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0570 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.60 |
InVivo Therapeutics Holdings Corp. (NVIV) today announced that its 2019 Annual Meeting of Stockholders, scheduled for June 11, 2019, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Annual Meeting will be reconvened July 2, 2019 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (SEC) on April 25, 2019. It has come to the Company’s attention that certain stockholders may have been unable to vote their shares through their broker or financial institutions, particularly if such shares are held through European institutions.
Nearly two years after halting multiple clinical trials due to the deaths of three participants for what's described as unrelated reasons, Kendall Square medical device maker InVivo Therapeutics Corp. has launched its first new trial of an implant it believes could help heal spinal cord injuries.
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first two patients have been enrolled into The INSPIRE 2.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). “Having the first two patients enrolled into the INSPIRE 2.0 Study is a critical milestone for the company and for the spinal cord injury patient population, as there continues to be inadequate treatment options for these patients. With eight clinical sites now open for enrollment, we remain optimistic about continuing to execute on the INSPIRE 2.0 study and will provide updates when appropriate,” commented Richard Toselli, M.D., President and Chief Executive Officer of InVivo.
InVivo Therapeutics Holdings Corp. (NVIV) (“InVivo” or the “Company”) today announced the presentation of the twelve-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). The findings were presented at the 2019 AANS Meeting in San Diego, CA through an e-poster titled, “Twelve Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury”, co-authored by Kee Kim, M.D., Department of Neurosurgery, UC-Davis, Sacramento, CA, K. Stuart Lee, M.D., Division of Neurosurgery, Vidant Health, Greenville, NC, Lee, Domagoj Coric, M.D., Carolina Neurosurgery and Spine, Charlotte, NC, Nicholas Theodore M.D., Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, and Richard Toselli, M.D., President and Chief Executive Officer of InVivo.
InVivo Therapeutics Holdings Corp. today reported financial results for the year ended December 31, 2018.
InVivo Therapeutics Holdings Corp. (NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announces the appointment of Richard Christopher as its Chief Financial Officer and Treasurer, effective January 14, 2019. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD, Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology.
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the LD Micro Main Event on Tuesday, December 4, 2018 at 7:30 am Pacific Time at the Luxe Hotel in Los Angeles, CA .
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 42 cents. In the final minutes of trading on Thursday, the company's shares hit $2.09. A year ago, they were trading ...
- Announces Western Institutional Review Board Approval for Select INSPIRE 2.0 Study Sites -
- Aims to evaluate the preclinical safety and feasibility of the Neuro-Spinal Scaffold™ with stem cells -
- Supports INSPIRE clinical investigation of the Neuro-Spinal Scaffold -
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am Eastern Time at the Sofitel Hotel in New York, New York. Dr. Toselli’s presentation will discuss recent company updates, including updates related to the Company’s INSPIRE 2.0 Study. A live webcast will be available at http://wsw.com/webcast/ladenburg4/nviv/, and a webcast replay will be available at the same address approximately one hour after the live webcast presentation.
InVivo Therapeutics Holdings Corp. (NVIV) today announced the complete 12-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). As previously announced by InVivo, 7 of 16 (44%) patients who reached the six-month primary endpoint visit in the INSPIRE study had an ASIA Impairment Scale (AIS) conversion at 6 months, which is the primary endpoint of the trial (defined as improvement in AIS grade from baseline for all evaluable patients at the six-month visit). The Objective Performance Criterion (OPC) (study success definition) for the study was a 25% AIS conversion rate based on the published conversion rates for thoracic spinal cord injury (SCI) reported in the literature.
The Cambridge, Massachusetts-based company said it had a loss of $7.48 per share. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $50. _____ ...
- Significant Increase in Operating Efficiency; Operating Expenses Decreased by 59% -
InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and warrant. In addition, the underwriter exercised its option to purchase an aggregate of 989,997 additional shares of common stock and additional warrants to purchase 989,997 shares of common stock at the public offering price of $2.00 per share and warrant, less the underwriting discounts and commissions.